Pharsight

Tolsura is owned by Mayne Pharma Intl.

Tolsura contains Itraconazole.

Tolsura has a total of 6 drug patents out of which 0 drug patents have expired.

Tolsura was authorised for market use on 11 December, 2018.

Tolsura is available in capsule;oral dosage forms.

Tolsura can be used as treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis.

The generics of Tolsura are possible to be released after 21 June, 2033.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8771739	MAYNE PHARMA INTL	Pharmaceutical compositions for poorly soluble drugs	Jul, 2023 (a month from now)
US10806792	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US10463740	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US9713642	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US8921374	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US9272046	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)